Clinical Scientist, Clinical Development
Spyre Therapeutics
Summary
As a Clinical Scientist at Spyre Therapeutics, you will play a key role in designing, executing, and interpreting clinical trials that support development of our novel antibody-based therapies. You will collaborate across functions (clinical operations, regulatory, translational science, biomarker teams) to ensure robust study designs, high-quality data generation and efficient progression of programs. You will bring scientific and operational expertise and act as a bridge between internal teams, external investigators and CRO partners. You will ensure the integrity, safety, and scientific validity of data collected during clinical studies.
Job description
Role Summary
As a Clinical Scientist at Spyre Therapeutics, you will play a key role in designing, executing, and interpreting clinical trials that support development of our novel antibody-based therapies. You will collaborate across functions (clinical operations, regulatory, translational science, biomarker teams) to ensure robust study designs, high-quality data generation and efficient progression of programs. You will bring scientific and operational expertise and act as a bridge between internal teams, external investigators and CRO partners. You will ensure the integrity, safety, and scientific validity of data collected during clinical studies.
Key Responsibilities
- Collaborate with clinical operations, data management and CRO, with a focus on ongoing clinical data review, to identify data trends, clean discrepancies, and ensure patient safety and protocol compliance.
- Perform regular, systematic reviews of clinical trial data, including adverse events, lab data, concomitant medications, medical histories and resolution of clinical data queries.
- Assist in Medical Monitor responsibilities.
- Contribute to study design and amendments in collaboration with internal and external stakeholders.
- Collaborate with Clinical Development, regulatory and other internal partners/stakeholders with authoring and submission of protocols, protocol amendments, regulatory filings, and other regulatory documentation.
- Assist with scientific oversight and decision-making support during trial execution: site selection, study start-up, monitoring of key trial metrics, risk-based quality oversight and study close-out.
- Write and/or review abstracts, posters, content for scientific meetings, conferences, other events and presentations, and other publicly distributed materials and coordinate further reviews with internal partners and stakeholders.
- Write clinical science sections of meeting packages and assist in the development and review of other clinical documentation required for regulatory submissions and other regulatory processes.
- Collaborate with regulatory affairs to ensure study designs meet regulatory standards (e.g., FDA/ICH, GCP) and support regulatory submissions and interactions.
- Develop and maintain clinical trial documentation (protocols, clinical study reports, investigator brochures, informed-consent forms, etc.).
- Monitor the competitive and scientific landscape in therapeutics space and contribute to strategic positioning of Spyre's pipeline programs.
- Additional duties as assigned.
Ideal Candidate
- 5+ years of clinical development experience in the biotech/pharma industry, ideally with at least 2 years in immunology, gastroenterology/IBD or immune-mediated disease area.
- Bachelor's degree in life sciences, clinical pharmacology, immunology or related discipline; advanced degree is a plus.
- Demonstrated experience in executing clinical trials IBD or other I&I therapeutic area.
- An understanding of clinical biomarkers, PK/PD modelling, patient stratification and immunologic endpoints.
- Familiarity with regulatory requirements (FDA/ICH guidelines, GCP) and Good Clinical Practice.
- Proven ability to work cross-functionally in a matrix organization (clinical operations, translational science, regulatory, QA).
- Excellent written and verbal communication skills, presentation and interpersonal skills; ability to influence diverse stakeholders.
- Comfortable working in a fast-paced, dynamic environment with ambiguity, and willing to wear multiple hats.
Requirements
- 5+ years of clinical development experience in the biotech/pharma industry
- At least 2 years in immunology, gastroenterology/IBD or immune-mediated disease area
- Bachelor's degree in life sciences, clinical pharmacology, immunology or related discipline
- Demonstrated experience in executing clinical trials in IBD or other I&I therapeutic area
- Understanding of clinical biomarkers, PK/PD modelling, patient stratification and immunologic endpoints
- Familiarity with regulatory requirements (FDA/ICH guidelines, GCP) and Good Clinical Practice
- Proven ability to work cross-functionally in a matrix organization
- Excellent written and verbal communication, presentation and interpersonal skills
- Comfortable working in a fast-paced, dynamic environment with ambiguity
Benefits
- Performance Bonus
- Equity Grants
- Health Insurance
- Welfare Benefits
- Retirement Benefits
- Unlimited PTO
- Professional Development
- Company-wide Shutdowns
Company overview
Spyre Therapeutics is a clinical-stage biotechnology company focused on developing next-generation treatments for inflammatory bowel disease (IBD) and other immune-mediated diseases. Founded in 2023 and headquartered in Waltham, Massachusetts, the company combines best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to create innovative therapies. Spyre's pipeline includes investigational extended half-life antibodies targeting key pathways such as α4β7, TL1A, and IL-23, designed to offer improved efficacy and convenience through less frequent dosing regimens. The company's approach involves engineering antibodies for prolonged activity in the body and formulating them for subcutaneous delivery as monotherapies or combination therapies. With a team of experienced professionals from across the biopharmaceutical industry, Spyre is advancing multiple clinical programs with six proof-of-concept readouts planned for 2026 across its SKYLINE and SKYWAY Phase 2 studies. The company aims to redefine the standard of care in IBD through long-acting antibodies and antibody combinations that could potentially offer quarterly or twice-yearly maintenance dosing for patients.